Literature DB >> 6354498

Effectiveness of leishmanization in the control of cutaneous leishmaniasis.

A Nadim, E Javadian, G Tahvildar-Bidruni, M Ghorbani.   

Abstract

To find out the effectiveness of leishmanization in the control of zoonotic cutaneous leishmaniasis, more than 250 persons were inoculated by the 5th subculture of a strain of L. tropica major kept on laboratory mice. About 47% took with incubation period ranging from less than one month to more than 1 year. The duration of the lesion was from 3 months 1/2 to 13 months 1/2. The two year incidence of the natural infection in this hyperendemic area was 0.8% for "takes", and 10.5% for "non-takes" and 40% for controls. By doing leishmanin skin test two years after inoculation, it is concluded that leishmanization has a protective effect of about 80% in this endemic area.

Entities:  

Mesh:

Year:  1983        PMID: 6354498

Source DB:  PubMed          Journal:  Bull Soc Pathol Exot Filiales


  49 in total

1.  Differential induction of cellular responses by live and dead Leishmania promastigotes in healthy donors.

Authors:  S Nylén; U Mörtberg; D Kovalenko; I Satti; K Engström; M Bakhiet; H Akuffo
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

2.  Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.

Authors:  Salvador Iborra; Javier Carrión; Charles Anderson; Carlos Alonso; David Sacks; Manuel Soto
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

Review 3.  Persistent parasites and immunologic memory in cutaneous leishmaniasis: implications for vaccine designs and vaccination strategies.

Authors:  Ifeoma Okwor; Jude Uzonna
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

4.  Prevention and treatment of cutaneous leishmaniasis in primates by using synthetic type D/A oligodeoxynucleotides expressing CpG motifs.

Authors:  Barbara Flynn; Vivian Wang; David L Sacks; Robert A Seder; Daniela Verthelyi
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

5.  Conditions influencing the efficacy of vaccination with live organisms against Leishmania major infection.

Authors:  Khaled S Tabbara; Nathan C Peters; Farhat Afrin; Susana Mendez; Sylvie Bertholet; Yasmine Belkaid; David L Sacks
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

6.  Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis.

Authors:  Marie Breton; Michel J Tremblay; Marc Ouellette; Barbara Papadopoulou
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

7.  Cutaneous Infection with Leishmania major Mediates Heterologous Protection against Visceral Infection with Leishmania infantum.

Authors:  Audrey Romano; Nicole A Doria; Jonatan Mendez; David L Sacks; Nathan C Peters
Journal:  J Immunol       Date:  2015-09-14       Impact factor: 5.422

8.  Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous Leishmaniasis but maintains its potency and durability.

Authors:  Susana Mendez; Khaled Tabbara; Yasmine Belkaid; Sylvie Bertholet; Daniela Verthelyi; Dennis Klinman; Robert A Seder; David L Sacks
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

9.  IL-7 receptor expression provides the potential for long-term survival of both CD62Lhigh central memory T cells and Th1 effector cells during Leishmania major infection.

Authors:  Sara L Colpitts; Nicole M Dalton; Phillip Scott
Journal:  J Immunol       Date:  2009-05-01       Impact factor: 5.422

10.  Evaluation of recombinant Leishmania polyprotein plus glucopyranosyl lipid A stable emulsion vaccines against sand fly-transmitted Leishmania major in C57BL/6 mice.

Authors:  Nathan C Peters; Sylvie Bertholet; Phillip G Lawyer; Melanie Charmoy; Audrey Romano; Flavia L Ribeiro-Gomes; Lisa W Stamper; David L Sacks
Journal:  J Immunol       Date:  2012-10-08       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.